S&P 500   3,203.11 (-0.73%)
DOW   26,705.95 (-0.61%)
QQQ   257.51 (-1.30%)
AAPL   384.37 (-1.67%)
MSFT   203.69 (-2.09%)
FB   238.42 (-0.77%)
GOOGL   1,501.09 (-1.04%)
AMZN   2,960.80 (-1.60%)
NVDA   403.26 (-1.43%)
CGC   17.87 (-1.54%)
BABA   243.17 (-2.42%)
MU   50.10 (-0.81%)
GE   7.11 (-0.42%)
TSLA   1,489.73 (-3.64%)
AMD   54.36 (-1.79%)
T   30.29 (+0.90%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   76.01 (-0.83%)
DIS   119.29 (-1.36%)
NFLX   519.33 (-0.75%)
BAC   24.02 (-2.36%)
BA   181.73 (-3.30%)
S&P 500   3,203.11 (-0.73%)
DOW   26,705.95 (-0.61%)
QQQ   257.51 (-1.30%)
AAPL   384.37 (-1.67%)
MSFT   203.69 (-2.09%)
FB   238.42 (-0.77%)
GOOGL   1,501.09 (-1.04%)
AMZN   2,960.80 (-1.60%)
NVDA   403.26 (-1.43%)
CGC   17.87 (-1.54%)
BABA   243.17 (-2.42%)
MU   50.10 (-0.81%)
GE   7.11 (-0.42%)
TSLA   1,489.73 (-3.64%)
AMD   54.36 (-1.79%)
T   30.29 (+0.90%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   76.01 (-0.83%)
DIS   119.29 (-1.36%)
NFLX   519.33 (-0.75%)
BAC   24.02 (-2.36%)
BA   181.73 (-3.30%)
S&P 500   3,203.11 (-0.73%)
DOW   26,705.95 (-0.61%)
QQQ   257.51 (-1.30%)
AAPL   384.37 (-1.67%)
MSFT   203.69 (-2.09%)
FB   238.42 (-0.77%)
GOOGL   1,501.09 (-1.04%)
AMZN   2,960.80 (-1.60%)
NVDA   403.26 (-1.43%)
CGC   17.87 (-1.54%)
BABA   243.17 (-2.42%)
MU   50.10 (-0.81%)
GE   7.11 (-0.42%)
TSLA   1,489.73 (-3.64%)
AMD   54.36 (-1.79%)
T   30.29 (+0.90%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   76.01 (-0.83%)
DIS   119.29 (-1.36%)
NFLX   519.33 (-0.75%)
BAC   24.02 (-2.36%)
BA   181.73 (-3.30%)
S&P 500   3,203.11 (-0.73%)
DOW   26,705.95 (-0.61%)
QQQ   257.51 (-1.30%)
AAPL   384.37 (-1.67%)
MSFT   203.69 (-2.09%)
FB   238.42 (-0.77%)
GOOGL   1,501.09 (-1.04%)
AMZN   2,960.80 (-1.60%)
NVDA   403.26 (-1.43%)
CGC   17.87 (-1.54%)
BABA   243.17 (-2.42%)
MU   50.10 (-0.81%)
GE   7.11 (-0.42%)
TSLA   1,489.73 (-3.64%)
AMD   54.36 (-1.79%)
T   30.29 (+0.90%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   76.01 (-0.83%)
DIS   119.29 (-1.36%)
NFLX   519.33 (-0.75%)
BAC   24.02 (-2.36%)
BA   181.73 (-3.30%)
Log in

NASDAQ:STOKStoke Therapeutics Stock Price, Forecast & News

$24.93
+0.50 (+2.05 %)
(As of 07/16/2020 12:18 PM ET)
Add
Compare
Today's Range
$24.77
Now: $24.93
$25.50
50-Day Range
$22.54
MA: $24.39
$29.73
52-Week Range
$15.82
Now: $24.93
$39.04
Volume1,333 shs
Average Volume179,410 shs
Market Capitalization$828.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STOK
CUSIPN/A
CIKN/A
Phone781-430-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.86 per share

Profitability

Net Income$-32,330,000.00

Miscellaneous

Employees44
Market Cap$828.17 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive STOK News and Ratings via Email

Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

How has Stoke Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STOK stock has increased by 26.4% and is now trading at $24.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Stoke Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stoke Therapeutics.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Stoke Therapeutics.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics (NASDAQ:STOK) posted its quarterly earnings data on Friday, May, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.02. View Stoke Therapeutics' earnings history.

What price target have analysts set for STOK?

6 Wall Street analysts have issued 1-year target prices for Stoke Therapeutics' stock. Their forecasts range from $30.00 to $46.00. On average, they anticipate Stoke Therapeutics' stock price to reach $36.80 in the next year. This suggests a possible upside of 47.6% from the stock's current price. View analysts' price targets for Stoke Therapeutics.

Has Stoke Therapeutics been receiving favorable news coverage?

Press coverage about STOK stock has been trending positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Stoke Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about Stoke Therapeutics.

Who are some of Stoke Therapeutics' key competitors?

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Akero Therapeutics (AKRO), LogicBio Therapeutics (LOGC), Precision BioSciences (DTIL), Gilead Sciences (GILD), Atreca (BCEL), Homology Medicines (FIXX) and Harpoon Therapeutics (HARP).

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:
  • Dr. Edward M. Kaye, CEO & Director (Age 70)
  • Dr. Adrian R. Krainer, Co-Founder & Director (Age 60)
  • Ms. Isabel Aznarez, Co-Founder, VP & Head of Biology
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer (Age 60)
  • Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 52)

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $24.93.

How big of a company is Stoke Therapeutics?

Stoke Therapeutics has a market capitalization of $828.17 million. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 44 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.